Mikhail Eydelman - 27 Feb 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, GEN COUNSEL & CORP SEC
Signature
Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
27 Feb 2025
Transactions value $
$-78,733
Form type
4
Filing time
03 Mar 2025, 21:15:27 UTC
Previous filing
07 Feb 2025
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +14,484 +51.3% $0.000000 42,706 27 Feb 2025 Direct F1
transaction PCVX Common Stock Tax liability $-34,319 -470 -1.1% $73.02 42,236 28 Feb 2025 Direct F2
transaction PCVX Common Stock Tax liability $-44,414 -616 -1.46% $72.10 41,620 03 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +48,357 $0.000000 48,357 27 Feb 2025 Common Stock 48,357 $74.22 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F3 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.